EC grants marketing authorisation for chronic hypoparathyroidism drug
The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is Ascendis Pharma’s prodrug of parathyroid hormone (PTH 1-34), administered once daily. Ascendis plans its first EU launch of YORVIPATH in January 2024… Read More